UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 3, 2022

Date of Report (date of earliest event reported)



Cutera, Inc.

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 000-50644 (Commission File Number) 77-0492262 (I.R.S. Employer Identification Number)

3240 Bayshore Blvd. Brisbane, California 94005 (Address of principal executive offices)

(415) 657-5500 (Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered					
Common Stock (\$0.001 par value)	CUTR	The NASDAQ Stock Market, LLC					

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company	
-------------------------	--

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02. Results of Operations and Financial Condition.

On November 3, 2022, Cutera, Inc. ("Cutera" or the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2022. Cutera hereby incorporates by reference herein the information set forth in its press release dated November 3, 2022, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it shall not create any implication that the affairs of Cutera have continued unchanged since such date.

The Company will host a conference call for interested parties commencing Tuesday, November 3, 2022 at 1:15 p.m. PDT (4:15 p.m. EDT), during which the Company will discuss the financial results. To participate in the conference call, dial 1-800-319-4610 (domestic) or +1-631-891-4304 (international). The conference call will be also available to interested parties through a live audio webcast and accessible through the Investor Relations section of the Cutera corporate website at www.cutera.com.

The information provided pursuant to this Item 2.02 is to be considered "furnished" pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of Cutera's reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing.

Except for the historical information contained in this report, the statements made by Cutera are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Cutera's future financial performance could differ significantly from the expectations of management and from results expressed or implied in the press release. Please refer to the last paragraph of the text portion of the press release for further discussion about forward-looking statements. For further information on risk factors, please refer to "Risk Factors" contained in Cutera's most recently filed Form 10-K and its subsequent filings with the Securities and Exchange Commission, as well as in the press release attached as Exhibit 99.1 hereto. Cutera disclaims any obligation or duty to update or modify these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description							
99.1	Press Release of Cutera, Inc. dated as of November 3, 2022.							
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)							

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUTERA, INC.

Date: November 3, 2022 /s/ ROHAN SETH

Rohan Seth

Chief Financial Officer



Cutera Announces Third Quarter 2022 Financial Results

Continued momentum in Capital equipment sales, posting 27% growth as reported and 32% in constant currency;

Strong Consumable product growth reflecting robust underlying treatment volumes;

Moving to full North American AviClear launch following successful limited commercial release;

Reiterating full-year revenue guidance despite foreign exchange headwinds, implying year-over-year constant currency growth of approximately 20%

BRISBANE, California, November 3, 2022 — Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2022.

Third Quarter 2022 Financial and Operational Highlights

- Consolidated revenue of \$62.8 million driven by capital equipment and consumable product demand.
- During Q3 2022, over 100 new active placements of AviClear devices, up from the over 50 in Q2 and slightly ahead of the previous 100 device Q3 commitment.
- Strong Consumable Product Revenue, up 66% as reported and 74% on a constant currency basis, reflecting robust underlying treatment volumes and the inclusion of AviClear patient procedure revenue.
- GAAP Gross margin of 54.5% in the quarter, compared to 58.2% in the prior-year period.
 - Excluding the 170 basis point impact from AviClear investments and foreign exchange headwinds of approximately 250 basis points, gross margin would have been 58.7%.
- GAAP Operating expenses were \$43.7 million in the quarter, compared to \$32.8 million in the prior-year period. Operating expenses during the period included \$8.1 million in AviClear spending in addition to \$1.4 million in ERP implementation expenses.
- GAAP Net loss was \$12.1million, compared to a Net loss of \$1.4 million in the prior-year period.
- Adjusted EBITDA was a loss of \$2.0 million, compared to a gain of \$5.1 million in the prior-year period.
 - Excluding AviClear impacts of \$7.9 million in the quarter and foreign exchange headwinds of \$3.1 million over the prior year period comparable adjusted EBITDA would have been \$9.1 million.

Key Revenue Metrics		ree Months Ended tember 30, 2022	% Change 2022 Vs 2021	Constant Currency			
Capital Equipment Skincare	\$	41.0 9.4	27 % -36 %		1103 1 10110 1:1001105	Three Months Ended September 30, 2022	Constant Currency
Consumables	\$	6.1	66 %	74 %	GAAP Margin %	54.5%	
Service Recurring	\$ \$	6.3 21.8	-6 % - 13 %		Non-GAAP Margin % Adjusted EBITDA	55.4% (\$2.0)	57.8% \$1.2
Total Revenue	\$	62.8	9 %		% Margin	-3.1 %	1.9%

Key Revenue Metrics	Nine Months Ended September 30, 2022		% Change 2022 Vs 2021	Constant Currency
Capital Equipment	\$	121.2	26 %	30 %
Skincare	\$	30.7	-21 %	-8 %
Consumables	\$	15.3	39 %	44 %
Service	\$	17.9	-9 %	-5 %
Recurring	\$	63.9	-8 %	1 %
Total Revenue	\$	185.0	12 %	18 %

Key Profit Metrics	Nine Months Ended September 30, 2022					
GAAP Margin %	54.6%	56.5%				
Non-GAAP Margin %	55.6%	57.4%				
Adjusted EBITDA	\$(7.4)	\$(0.3)				
% Margin	-4.0 %	-0.2 %				

[&]quot;I am pleased by the momentum we continue to see in our core business, as prior investments in sales force expansion deliver strong results in both our capital and consumables product segments across North America and other direct-sales markets. We remain watchful to the global macroeconomic conditions and are prepared to respond quickly if warranted. Based upon our current view, the strength of our third quarter performance, and our capital equipment pipeline, we remain encouraged by the resilience of our core markets," commented Dave Mowry, Chief Executive Officer of Cutera, Inc.

2022 Outlook

Based upon our results year-to-date, despite unprecedented foreign exchange volatility Cutera expects to finish 2022 at the upper end of revenue guidance of \$255 million to \$260 million, fully absorbing the impact of approximately \$17 million of currency headwinds. This implies constant currency growth of roughly 18% to 20% over the prior year.

Management now anticipates the placement of an additional 200 AviClear devices during the fourth quarter of 2022, bringing the total number of active AviClear platforms entering FY 2023 to approximately 350.

Conference Call

The Company's management will host a conference call to discuss these results and related matters today at 1:15 p.m. PT (4:15 p.m. ET). Participating in the call will be Dave Mowry, Chief Executive Officer, and Rohan Seth, Chief Financial Officer.

To participate in the conference call, dial 1-800-319-4610 (domestic) or + 1-631-891-4304 (international).

The call will also be a webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations and net income (loss) per share. Non-GAAP adjustments include stock-based compensation, depreciation, amortization, executive and other non-recurring severance costs, customer relationship management ("CRM") and enterprise resource planning ("ERP") system costs, non-recurring legal and litigation costs, and the loss on extinguishment of convertible notes. From time to time in the future, there may be other items that we may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. The Company has not provided a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability, limited

[&]quot;During the quarter, in addition to setting an all-time high for 3Q capital sales in North America, our sales team executed the second phase of our Limited Commercial Release, placing over 100 additional active AviClear devices into the field. These efforts enabled us to validate several new processes and as a result in November we will move to a full launch of this revolutionary product and procedure in North America, slightly ahead of our previous plans.

visibility, unpredictability, or unique non-recurring nature of the items. Forward-looking non-GAAP measures include adjusted EBITDA. The Company defines adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, stock-based compensation, executive and other non-recurring separation costs, customer relationship management and enterprise resource planning system costs, non-recurring legal and litigation costs, and losses on the extinguishment of convertible notes.

Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, regularly and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

Executive and other non-recurring severance costs. We have excluded costs associated with the resignation of our former Executive Officers in calculating our non-GAAP operating expenses and net income measures. We exclude these and other non-recurring employee separation costs because we believe that these items do not reflect future operating expenses;

Customer Relationship Management. We have excluded CRM system costs related to direct and incremental costs incurred in connection with our multiphase implementation of a new CRM solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance;

Enterprise Resource Planning. We have excluded ERP system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance;

Non-recurring legal and litigation costs. We have excluded costs incurred related to third-party litigation and disputes, that are non-recurring; and

Loss on extinguishment of convertible notes. We have excluded the loss on extinguishment of convertible notes. We excluded this loss because we believe it is non-recurring.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include but are not limited to, Cutera's plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company's actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "should," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "foresee" or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company's

control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the third quarter ended September 30, 2022, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

Cutera, Inc. Greg Barker VP, Corporate FP&A 415-657-5500 IR@cutera.com

CUTERA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)

Assets Current Current <th< th=""><th></th><th>Se</th><th>eptember 30, 2022</th><th colspan="3">December 31, 2021</th></th<>		Se	eptember 30, 2022	December 31, 2021		
Cash and cash equivalents \$ 45,880 \$ 164,164 Marketable investments 204,946 — Accounts receivable, net 35,876 31,449 Inventories, net 55,938 39,503 Other current assets 23,672 14,545 Total current assets 366,312 249,661 Property and equipment, net 34,479 3,019 Deferred tax assets 626 778 Goodwill 13,33 1,339 Operating lease right-of-use assets 11,668 10,109 Other long-term assets 11,668 10,109 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities \$ 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accounting lease liabilities \$ 9,251 7,390 Deferred revenue 10,579 9,490 Total current liabilities 96,253 73,900 Deferred revenue	Assets	-				
Marketable investments 204,946 — Accounts receivable, net 35,876 31,449 Inventories, net 55,938 39,503 Other current assets 23,672 14,545 Total current assets 366,312 249,661 Property and equipment, net 34,479 3,019 Deferred tax assets 626 778 Goodwill 1,339 1,339 Operating lease right-of-use assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities \$ 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accountiliabilities 50,791 \$ 54,100 Operating leases liabilities 9,30 \$ 7,891 Accountila paid-in current portion 1,822 1,335 Operating lease liabilities, net of current portion 1,822 1,348 Convertible	Current assets:					
Accounts receivable, net 35,876 31,499 Inventories, net 55,938 39,503 Other current assets and prepaid expenses 23,672 14,545 Total current assets 366,312 249,661 Property and equipment, net 34,479 3,019 Deferred tax assets 666 778 Goodwill 1,339 1,339 Operating lease right-of-use assets 11,668 10,169 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Urrent liabilities \$ 34,176 \$ 7,891 Accrued liabilities \$ 7,891 \$ 4,100 Operating leases liabilities \$ 7,891 \$ 4,100 Operating leases liabilities \$ 7,991 \$ 4,100 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,622 1,342 <	Cash and cash equivalents	\$	45,880	\$	164,164	
Inventories, net 55,938 39,503 Other current assets and prepaid expenses 23,672 14,545 Total current assets 366,312 249,661 Property and equipment, net 34,479 3,019 Deferred tax assets 626 778 Goodwill 1,339 1,339 Operating lease right-of-use assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Intervent liabilities 5 428,157 \$ 280,293 Accounts payable \$ 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accounts payable \$ 5,791 \$ 4,100 Operating leases liabilities 5,791 \$ 4,100 Operating leases liabilities 9,892 73,900 Total current liabilities 9,872 73,900 Deferred revenue, net of current portion 1,822 1,348 Operating lease liabilities, net of current portion 1,622 1,348 Operating lease, liabilities, net of curr	Marketable investments		204,946		_	
Other current assets and prepaid expenses 23,672 14,545 Total current assets 366,312 249,661 Property and equipment, net 34,479 3,019 Deferred tax assets 626 778 Goodwill 13,033 1,339 Operating lease right-of-use assets 11,668 10,169 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Exercise Liabilities \$ 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accounts payable \$ 50,791 \$ 54,000 Accounts payable \$ 50,791 \$ 54,000 Accounts payable \$ 50,791 \$ 54,000 Accure Ilabilities \$ 50,791 \$ 54,000 Operating lease liabilities \$ 34,000 \$ 34,000 Total current liabilities \$ 36,000 \$ 34,000 Operating lease liabilities, net of current portion \$ 1,822 \$ 1,335 <td>Accounts receivable, net</td> <td></td> <td>35,876</td> <td></td> <td>31,449</td>	Accounts receivable, net		35,876		31,449	
Total current assets 366,312 249,661 Property and equipment, net 34,479 3,019 Deferred tax assets 626 778 Goodwill 1,339 1,339 Operating lease right-of-use assets 13,033 14,627 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities \$ 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 50,791 54,100 Operating leases liabilities 9,825 73,900 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763	Inventories, net		55,938		39,503	
Property and equipment, net 34,479 3,019 Deferred tax assets 626 778 Goodwill 1,339 1,339 Operating lease right-of-use assets 13,033 14,627 Other long-term assets 11,668 10,169 Restricted cash 700 70 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 11,642 13,483 Operating lease liabilities, net of current portion 11,642 13,483 Operating lease liabilities 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 20 18 Additional paid-in capital <td< td=""><td>Other current assets and prepaid expenses</td><td></td><td>23,672</td><td></td><td>14,545</td></td<>	Other current assets and prepaid expenses		23,672		14,545	
Deferred tax assets 626 778 Godwill 1,339 1,339 Operating lease right-of-use assets 13,033 14,628 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities: Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 1,622 13,483 Other long-term liabilities 685 763 Total long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: Common stock 20 18	Total current assets		366,312		249,661	
Deferred tax assets 626 778 Godwill 1,339 1,339 Operating lease right-of-use assets 13,033 14,628 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities: Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 1,622 13,483 Other long-term liabilities 685 763 Total long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: Common stock 20 18	Providence in the control of		24.470		2.010	
Goodwill 1,339 1,339 Operating lease right-of-use assets 13,033 14,627 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Users Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockkholders' equity: Common stock 20 18 Additional paid-in capital 418,535 <td></td> <td></td> <td></td> <td></td> <td></td>						
Operating lease right-of-use assets 13,033 14,627 Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Urrent liabilities Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 268 763 Total liabilities 20 18 Stockholders' equity: 20 18 Common stock 20 18 Additional pairal in capital <td></td> <td></td> <td></td> <td></td> <td></td>						
Other long-term assets 11,668 10,169 Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities: Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 685 763 Total liabilities 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173)						
Restricted cash 700 700 Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total s						
Total assets \$ 428,157 \$ 280,293 Liabilities and Stockholders' Equity Current liabilities: Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,348 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 56,560						
Liabilities and Stockholders' Equity Current liabilities: Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 56,569		<u></u>		r.		
Current liabilities: 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 56,569	Total assets	<u>\$</u>	428,15/	\$	280,293	
Current liabilities: 34,176 \$ 7,891 Accounts payable \$ 34,176 \$ 7,891 Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 56,569	Liabilities and Stockholders' Equity					
Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569						
Accrued liabilities 50,791 54,100 Operating leases liabilities 2,712 2,419 Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	Accounts payable	\$	34,176	\$	7,891	
Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569						
Deferred revenue 10,579 9,490 Total current liabilities 98,258 73,900 Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	Operating leases liabilities		2,712		2,419	
Deferred revenue, net of current portion 1,822 1,335 Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569			10,579			
Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	Total current liabilities		98,258		73,900	
Operating lease liabilities, net of current portion 11,642 13,483 Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569						
Convertible notes, net of unamortized debt issuance costs 300,256 134,243 Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	•					
Other long-term liabilities 685 763 Total liabilities 412,663 223,724 Stockholders' equity: 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569						
Total liabilities 412,663 223,724 Stockholders' equity: Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	•					
Stockholders' equity: Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569						
Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	Total liabilities		412,663		223,724	
Common stock 20 18 Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569	Stockholders' equity:					
Additional paid-in capital 148,535 114,724 Accumulated other comprehensive loss (336) — Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569			20		18	
Accumulated other comprehensive loss(336)—Accumulated deficit(132,725)(58,173)Total stockholders' equity15,49456,569	Additional paid-in capital		148,535			
Accumulated deficit (132,725) (58,173) Total stockholders' equity 15,494 56,569			,			
Total stockholders' equity 15,494 56,569					(58,173)	
		\$		\$		

CUTERA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited)

		Three Mo	nths	s Ended		Nine Mor	ıth	ıs Ended
	Se	eptember 30, 2022		September 30, 2021	_	September 30, 2022	_	September 30, 2021
Products	\$	56,540	\$	50,694	\$	167,195	\$	146,056
Service		6,268		6,690		17,851		19,585
Total net revenue		62,808		57,384		185,046		165,641
Products		25,255		20,259		74,066		59,483
Service		3,305		3,700		9,900		11,234
Total cost of revenue		28,560	'	23,959		83,966		70,717
Gross profit		34,248		33,425		101,080		94,924
Gross margin %		54.5 %		58.2 %		54.6 %		57.3 %
Operating expenses:								
Sales and marketing		26,488		19,190		78,433		52,668
Research and development		6,389		5,802		19,747		14,764
General and administrative		10,804		7,807		35,554		23,633
Total operating expenses		43,681		32,799		133,734		91,065
(Loss) income from operations		(9,433)		626		(32,654)		3,859
Interest and other (expense) income, net								
Amortization of debt issuance costs		(400)		(225)		(917)		(492)
Interest on convertible notes		(1,739)		(768)		(3,666)		(1,737)
Loss on extinguishment of convertible notes		_		_		(34,423)		_
Gain on extinguishment of PPP loan		_		_		_		7,185
Other expense, net		265		(561)		(2,018)		(1,976)
(Loss) income before income taxes		(11,307)		(928)		(73,678)		6,839
Income tax expense		827		462		874		842
Net (loss) income	\$	(12,134)	\$	(1,390)	\$	(74,552)	\$	5,997
Net (loss) income per share:								
Basic	\$	(0.62)	\$	(0.08)	\$	(3.95)	\$	0.34
Diluted	\$	(0.62)	\$	(80.0)	\$	(3.95)	\$	0.33
Weighted-average number of shares used in per share calculations:								
Basic		19,593		17,945		18,897		17,860
Diluted		19,593		17,945		18,897		18,327

CUTERA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

(unaudited)

		Three Mo	nths Ended	Nine Months Ended			
	Sep	otember 30, 2022	September 30, 2021	September 30, 2022	September 30, 2021		
Cash flows from operating activities:							
Net (loss) income	\$	(12,134)	\$ (1,390)	\$ (74,552)	\$ 5,997		
Adjustments to reconcile net (loss) income to net cash used in operating activitie	s:						
Stock-based compensation		4,245	3,742	13,021	8,507		
Depreciation and amortization		674	307	1,603	1,014		
Amortization of contract acquisition costs		596	427	1,815	1,430		
Amortization of debt issuance costs		400	225	917	492		
Unrealized gain on foreign exchange forward		(292)	_	(292)	_		
Impairment of capitalized cloud computing costs		_	_	_	182		
Change in deferred tax assets		72	3	152	54		
Provision for excess and obsolete inventories		(448)	636	110	1,335		
Provision for credit losses		268	(391)	677	101		
Loss (gain) on sale of property and equipment		23	37	86	(45		
PPP loan forgiveness		_	_	_	(7,185		
Change in right-of-use asset		668	1,077	1,976	1,681		
Loss on extinguishment of convertible notes		_	_	34,423	_		
Changes in assets and liabilities:							
Accounts receivable, net		(3,996)	(4,466)	(5,104)	(8,899		
Inventories, net		(10,666)	(1,604)	(28,725)	(8,261		
Other current assets and prepaid expenses		(5,801)	(4,494)	(8,835)	(4,571		
Other long-term assets		(2,573)	(1,767)	(3,644)	(3,487		
Accounts payable		5,671	1,049	20,442	575		
Accrued liabilities		3,194	2,129	(3,684)	11,782		
Operating lease liabilities		(658)	(1,043)	(1,930)	(1,573		
Deferred revenue		874	(723)	1,576	(557		
Net cash used in operating activities		(19,883)	(6,246)	(49,968)	(1,428		
Cash flows from investing activities:							
Acquisition of property, equipment and software		(5,869)	(12)	(14,107)	(382		
Disposal of property and equipment		_	_	_	71		
Purchase of marketable and long-term investments		47,000	_	47,000	_		
Purchase of marketable investments		(48,973)	_	(252,282)	_		
Net cash used in investing activities		(7,842)	(12)	(219,389)	(311		
Cash flows from financing activities:							
Proceeds from exercise of stock options and employee stock purchase plan		248	158	1,687	2,056		
Taxes paid related to net share settlement of equity awards		(586)	(511)	(4,820)	(1,963		
Purchase of capped call			`_	(31,671)	(16,134		
Payment of issuance costs of capped call		(353)	_	(353)			
Proceeds from issuance of convertible notes			_	240,000	138,250		
Payment of issuance costs of convertible notes		(646)	_	(7,602)	(4,717		
Extinguishment of convertible notes		`	_	(45,777)	_		
Payments on finance lease obligations		(108)	(103)	(391)	(314		
Net cash (used in) provided by financing activities		(1,445)	(456)	151,073	117,178		
Net (decrease) increase in cash, cash equivalents and restricted cash		(29,170)	(6,714)	(118,284)	115,439		
Cash, cash equivalents, and restricted cash at beginning of period		75,750	169,200	164,864	47,047		
Cash, cash equivalents, and restricted cash at end of period	\$	46,580	\$ 162,486		\$ 162,486		

CUTERA, INC. CONSOLIDATED FINANCIAL HIGHLIGHTS (in thousands, except percentage data) (unaudited)

	Three Months Ended			% Change	Nine Mor	% Change			
	Septe	mber 30, 2022	Sept	ember 30, 2021	2022 Vs 2021	September 30, 2022		September 30, 2021	2022 Vs 2021
Revenue By Geography:									
North America	\$	33,258	\$	26,710	+24.5 %	\$ 94,350	\$	75,794	+24.5 %
Japan		15,263		19,335	-21.1 %	47,940		53,311	-10.1 %
Rest of World		14,287		11,339	+26.0 %	42,756		36,536	+17.0 %
Total Net Revenue	\$	62,808	\$	57,384	+9.5 %	\$ 185,046	\$	165,641	+11.7 %
International as a percentage of total revenue		47.0 %		53.5 %		49.0 %		54.2 %	
Revenue By Product Category:									
Systems	•	25.250		20.000	22.5.0/	# # 2.200		== 0=0	. 57.0.0/
– North America	\$	25,359	\$	20,680	+22.6 %	-,	\$	57,353	+27.8 %
 Rest of World (including Japan) 		15,626		11,511	+35.7 %	47,854		38,726	+23.6 %
Total Systems		40,985		32,191	+27.3 %	121,152		96,079	+26.1 %
Consumables		6,119		3,684	+66.1 %	15,320		11,040	+38.8 %
Skincare		9,436		14,819	-36.3 %	30,723		38,937	-21.1 %
Total Products		56,540		50,694	+11.5 %	167,195		146,056	+14.5 %
Service		6,268		6,690	-6.3 %	17,851		19,585	-8.9 %
Total Net Revenue	\$	62,808	\$	57,384	+9.5 %	\$ 185,046	\$	165,641	+11.7 %

	Three Months Ended					Nine Months Ended				
	September 3	0, 2022	9	September 30, 2021	September 30, 2022			September 30, 2021		
Pre-tax Stock-Based Compensation Expense:										
Cost of revenue	\$	471	\$	330	\$	1,430	\$	908		
Sales and marketing		1,641		711		3,855		1,954		
Research and development		466		1,020		2,513		1,628		
General and administrative		1,667		1,681		5,223		4,017		
	\$	4,245	\$	3,742	\$	13,021	\$	8,507		

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

	Three Months Ended September 30, 2022								
		GAAP	Depreciation and Amortization	Stock-Based Compensation	ERP Implementation	Legal - Lutronic	Severance	Other Adjustments	Non-GAAP
Net revenue	\$	62,808	_	_	_	_	_	_	\$ 62,808
Cost of revenue		28,560	(359)	(471)	_	_	(26)	290	27,994
Gross profit		34,248	359	471	_	_	26	(290)	34,814
Gross margin %		54.5 %							55.4 %
Operating expenses:									
Sales and marketing		26,488	(715)	(1,641)	_	_	(262)	_	23,870
Research and development		6,389	(67)	(466)	_	_	(88)	_	5,768
General and administrative		10,804	(54)	(1,667)	(1,351)	(566)	(39)	_	7,127
Total operating expenses		43,681	(836)	(3,774)	(1,351)	(566)	(389)		36,765
(Loss) income from operations		(9,433)	1,195	4,245	1,351	566	415	(290)	(1,951)
Interest and other income (expense), net									
Amortization of debt issuance costs		(400)	_	_	_	_	_	_	(400)
Interest on convertible notes		(1,739)	_	_	_	_	_	_	(1,739)
Other income		265							265
Total interest and other expense, net		(1,874)		_					(1,874)
(Loss) income before income taxes		(11,307)	1,195	4,245	1,351	566	415	(290)	(3,825)
Income taxes expense		827	_	_	_	_	_	_	827
Net (loss) income	\$	(12,134)	\$ 1,195	\$ 4,245	\$ 1,351	\$ 566	\$ 415	\$ (290)	\$ (4,652)
Net loss per share:									
Basic	\$	(0.62)							\$ (0.24)
Weighted-average number of shares used in per s	hare calcu	lations:							
Basic		19,593							19,593
Operating expenses as a % of net revenue		GAAP							Non-GAAP
Sales and marketing		42.2 %							38.0 %
Research and development		10.2 %							9.2 %

58.5 %

17.2 % 69.6 %

General and administrative

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

	Three Months Ended September 30, 2021							
		GAAP	Depreciation and Amortization	Stock-Based Compensation	CRM and ERP Implementation	Legal - Lutronic	Other Adjustments	Non-GAAP
Net revenue	\$	57,384	_	_	_	_	_	\$ 57,384
Cost of revenue		23,959	(132)	(330)	_	_	445	23,942
Gross profit		33,425	132	330	_	_	(445)	33,442
Gross margin %		58.2 %						58.3 %
Operating expenses:								
Sales and marketing		19,190	(549)	(711)	_	_	_	17,930
Research and development		5,802	(49)	(1,020)	_	_	_	4,733
General and administrative		7,807	(8)	(1,681)	(128)	(288)		5,702
Total operating expenses		32,799	(606)	(3,412)	(128)	(288)	_	28,365
(Loss) income from operations	'	626	738	3,742	128	288	(445)	5,077
Interest and other expense, net								
Amortization of debt issuance costs		(225)	_	_	_	_	_	(225)
Interest on convertible notes		(768)	_	_	_	_	_	(768)
Other expense		(561)						(561)
Total interest and other expense, net		(1,554)		_				(1,554)
(Loss) income before income taxes		(928)	738	3,742	128	288	(445)	3,523
Income tax expense		462						462
Net (loss) income	\$	(1,390)	\$ 738	\$ 3,742	\$ 128	\$ 288	\$ (445)	\$ 3,061
Net (loss) income per share:								
Basic	\$	(80.0)						\$ 0.17
Weighted-average number of shares used in per s	share cal	culations:						
Basic		17,945						17,945
Operating expenses as a % of net revenue		GAAP						Non-GAAP
Sales and marketing		33.4 %						31.2 %

8.2 %

9.9 % 49.3 %

10.1 %

13.6 % 57.1 %

Research and development

General and administrative

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

	Nine Months Ended September 30, 2022								
	GAAP	Depreciation and Amortization	Stock-Based Compensation	ERP Implementation	Legal - Lutronic	Severance	Other Adjustments	Loss on Extinguishment of Convertible Notes	Non-GAAP
Net revenue	\$ 185,046	_	_	_	_	_	_	_	\$ 185,046
Cost of revenue	83,966	(596)	(1,430)	_	_	(26)	290	_	82,204
Gross profit	101,080	596	1,430	_	_	26	(290)		102,842
Gross margin %	54.6 %								55.6 %
Operating expenses:									
Sales and marketing	78,433	(2,328)	(3,855)	_	_	(262)	_	_	71,988
Research and development	19,747	(180)	(2,513)	_	_	(88)	_	_	16,966
General and administrative	35,554	(238)	(5,223)	(7,712)	(1,062)	(39)	_	_	21,280
Total operating expenses	133,734	(2,746)	(11,591)	(7,712)	(1,062)	(389)	_		110,234
(Loss) income from operations	(32,654)	3,342	13,021	7,712	1,062	415	(290)		(7,392
Interest and other (expense) income, net		,	·	,	ŕ		,		· · ·
Amortization of debt issuance costs	(917)	_	_	_	_	_	_	_	(917)
Interest on convertible notes	(3,666)	_	_	_	_	_	_	_	(3,666)
Loss on extinguishment of convertible notes	(34,423)			_	_	_	_	34,423	_
Other expense	(2,018)	_	_	_	_	_	_	_	(2,018)
Total interest and other expense, net	(41,024)		_	_	_		_	34,423	(6,601)
(Loss) income before income taxes	(73,678)	3,342	13,021	7,712	1,062	415	(290)	34,423	(13,993)
Income tax expense	874	_	_	_	_	_	_	_	874
Net (loss) income	\$(74,552)	\$3,342	\$13,021	\$7,712	\$1,062	\$415	\$(290)	\$34,423	\$(14,867
Net loss per share:									
Basic	\$(3.95)								\$(0.79
Weighted-average number of shares calculations:	used in per share								
Basic	18,897								18,897
Operating expenses as a % of net revenue	GAAP								Non-GAAI
Sales and marketing	42.4 %								38.9 %
Research and development	10.7 %								9.2 %
General and administrative	19.2 %								11.5 %

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

	Nine Months Ended September 30, 2021								
		GAAP	Depreciation and Amortization	Stock-Based Compensation	CRM and ERP Implementation	Severance (RIF)	Legal - Lutronic	Other Adjustments	Non-GAAP
Net revenue	\$	165,641	_	_	_	_	_	_	\$ 165,641
Cost of revenue		70,717	(432)	(908)	_	_	_	791	70,168
Gross profit	-	94,924	432	908	_			(791)	95,473
Gross margin %		57.3 %							57.6 %
Operating expenses:									
Sales and marketing		52,668	(1,827)	(1,954)	(182)	(638)	_	_	48,067
Research and development		14,764	(133)	(1,628)	_	_	_	_	13,003
General and administrative		23,633	(56)	(4,017)	(605)		(979)		17,976
Total operating expenses		91,065	(2,016)	(7,599)	(787)	(638)	(979)		79,046
(Loss) income from operations		3,859	2,448	8,507	787	638	979	(791)	16,427
Interest and other income (expense), net									
Amortization of debt issuance costs		(492)	_	_	_	_	_	_	(492)
Interest on convertible notes		(1,737)	_	_	_	_	_	_	(1,737)
Gain on extinguishment of PPP loan		7,185	_	_	_	_	_	(7,185)	_
Other expense		(1,976)							(1,976)
Total interest and other income (expense), net		2,980	_	_	_	_	_	(7,185)	(4,205)
Income (loss) before income taxes		6,839	2,448	8,507	787	638	979	(7,976)	12,222
Income tax expense		842	_	_	_	_	_	_	842
Net income (loss)	\$	5,997	\$ 2,448	\$ 8,507	\$ 787	\$ 638	\$ 979	\$ (7,976)	\$ 11,380
Net income per share:									
Basic	\$	0.34							\$ 0.64
Weighted-average number of shares used in per	share calcu	ılations:							
		17,860							17,860
Operating expenses as a % of net revenue		GAAP							Non-GAAP
Sales and marketing		31.8 %							29.0 %
Research and development		8.9 %							7.9 %

10.9 %

47.8 %

14.3 %

55.0 %

General and administrative

CUTERA, INC. RECONCILIATION OF LOSS TO ADJUSTED EBITDA (in thousands) (unaudited)

	Three	Months Ended	Nine Months Ended			
		September 30, 2022				
Net loss	ф	(12.124)	¢ (74 FF2)			
	\$	(12,134)	\$ (74,552)			
Adjustments:						
Depreciation and amortization		1,195	3,342			
Stock-based compensation		4,245	13,021			
ERP implementation cost		1,351	7,712			
Legal - Lutronic		566	1,062			
Severance		415	415			
Other adjustments		(290)	(290)			
Interest and other expense, net		1,874	41,024			
Income tax expense		827	874			
Total adjustments		10,183	67,160			
Adjusted EBITDA		\$(1,951)	\$(7,392)			